Atorvastatin and Conditioned Media from Atorvastatin-Treated Human Hematopoietic Stem/Progenitor-Derived Cells Show Proangiogenic Activity In Vitro but Not In Vivo

Figure 4

Treatment with atorvastatin does not change the levels of tested growth factors and mediators of inflammation. Heat map showing the fold change in the concentration of tested factors produced by cells treated with atorvastatin in comparison to cells treated with a vehicle () (a). Heat map showing the fold change in the concentration of tested factors produced by cells treated with 30 μmol/L atorvastatin for 48, 96, or 144 hours () (b). Mean particle number (c); mode particle size (d); or mean particle size (e) of microvesicles produced by CD34⁺ cells treated for 48 hours either with 30 μmol/L atorvastatin or with DMSO. Concentrations of secreted factors were assessed with Luminex; microvesicles were assessed with the NanoSight NTA platform ().

(a)

(b)

(c)

(d)

(e)